Premium
Nizatidine disposition in subjects with normal and impaired renal function
Author(s) -
Aronoff George R,
Bergstrom Richard F,
Bopp Ronald J,
Sloan Rebecca S,
Callaghan John T
Publication year - 1988
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1988.97
Subject(s) - medicine , volume of distribution , pharmacokinetics , hemodialysis , clinical pharmacology , renal function , creatinine , pharmacology , urology
To test the hypothesis that renal insufficiency alters nizatidine disposition, we determined the pharmacokinetics of nizatidine and its major metabolite after a single oral dose in normal volunteers and patients with various degrees of renal dysfunction, after a single intravenous dose in normal volunteers and patients with severe renal failure and during hemodialysis. After intravenous administration the elimination half‐life increased from 1.5 ± 0.2 hours in normal volunteers to 6.9 ± 3.3 hours in patients with renal failure. The plasma clearance decreased from 0.59 ± 0.07 L/kg/hr in normal volunteers to 0.14 ± 0.02 L/kg/hr in patients with renal failure. Nizatidine bioavailability was nearly 100% in normal volunteers but decreased to 75% in patients with renal failure. The volume of distribution was 1.3 ± 0.1 L/kg in normal volunteers and was not different in patients with renal failure. Nizatidine protein binding was about 30% in normal and uremic plasma. The drug was not substantially removed by hemodialysis. Patients with creatinine clearances less than 50 ml/min/1.73 m 2 should receive 150 mg nizatidine once each evening. Patients with creatinine clearances less than 20 ml/min/1.73 m 2 should receive 150 mg nizatidine every other night. Clinical Pharmacology and Therapeutics (1988) 43 , 688–695; doi: 10.1038/clpt.1988.97